SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The company witnessed a 20.80% growth in the revenue at Rs. 191.58 millions for the quarter ended March 2022 as compared to Rs. 158.59 millions during the year-ago period.The Net Loss for the quarter ended March 2022 is Rs. -113.14 millions as compared to Net Loss of Rs. -69.87 millions of corresponding quarter ended March 2021 Operating profit Margin for the quarter ended March 2022 further decreased to -89.85% as compared to -40.81% of corresponding quarter ended March 2021


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202203 202103 % Var 202203 202103 % Var 202203 202103 % Var
Sales 191.58 158.59 20.80 597.03 537.00 11.18 597.03 537.00 11.18
Other Income 7.93 4.44 78.60 11.56 6.21 86.15 11.56 6.21 86.15
PBIDT -89.85 -40.81 120.17 -328.39 -169.56 93.67 -328.39 -169.56 93.67
Interest 2.80 14.93 -81.25 53.91 62.79 -14.14 53.91 62.79 -14.14
PBDT -92.65 -55.74 66.22 -382.30 -232.35 64.54 -382.30 -232.35 64.54
Depreciation 20.49 14.13 45.01 62.97 51.24 22.89 62.97 51.24 22.89
PBT -113.14 -69.87 61.93 -445.27 -283.59 57.01 -445.27 -283.59 57.01
TAX 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PAT -113.14 -69.87 61.93 -445.27 -283.59 57.01 -445.27 -283.59 57.01
Equity 215.61 196.21 9.89 215.61 196.21 9.89 215.61 196.21 9.89
PBIDTM(%) -46.90 -25.73 82.25 -55.00 -31.58 74.20 -55.00 -31.58 74.20

Krebs Biochem.&Inds Share Price

60.90 -0.12 (-0.20%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×